Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 187

Showing 1-25 of 187 citing articles:

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 12, pp. 1874-2071
Open Access | Times Cited: 1573
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 698
Direct cardiac effects of SGLT2 inhibitors
Sha Chen, Ruben Coronel, Markus W. Hollmann, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 110
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 104
Hypertension management in patients with cardiovascular comorbidities
Lucas Lauder, Felix Mahfoud, Michel Azizi, et al.
European Heart Journal (2022) Vol. 44, Iss. 23, pp. 2066-2077
Open Access | Times Cited: 101
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
Dario Giugliano, Miriam Longo, Simona Signoriello, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 99
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
Ildiko Lingvay, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.
Obesity (2022) Vol. 31, Iss. 1, pp. 111-122
Open Access | Times Cited: 74
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, et al.
European Stroke Journal (2024) Vol. 9, Iss. 3, pp. 530-539
Open Access | Times Cited: 20
Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials
Frederick Berro Rivera, Linnaeus Louisse A. Cruz, John Vincent Magalong, et al.
American Journal of Preventive Cardiology (2024) Vol. 18, pp. 100679-100679
Open Access | Times Cited: 20
2024 Clinical practice guidelines for Hypertension in adults
Ж. Д. Кобалава, А. О. Конради, С. В. Недогода, et al.
Russian Journal of Cardiology (2024) Vol. 29, Iss. 9, pp. 6117-6117
Open Access | Times Cited: 19
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lee‐Ling Lim, Elaine Chow, Juliana C.N. Chan
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 3, pp. 151-163
Closed Access | Times Cited: 53
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
Ronald Goldenberg, Alice Cheng, Tess Fitzpatrick, et al.
Stroke (2022) Vol. 53, Iss. 5, pp. 1813-1822
Open Access | Times Cited: 40
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
João Sérgio Neves, Francisco Vasques‐Nóvoa, Marta Borges‐Canha, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 189-197
Open Access | Times Cited: 39
Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
André Scheen
Annales d Endocrinologie (2023) Vol. 84, Iss. 2, pp. 316-321
Closed Access | Times Cited: 34
Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials
João Pedro Ferreira, Francisca Saraiva, Abhinav Sharma, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1495-1502
Open Access | Times Cited: 34
Advances in the management of type 2 diabetes in adults
Rodolfo J. Galindo, Jennifer M. Trujillo, Cecilia C. Low Wang, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000372-e000372
Open Access | Times Cited: 30
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
Sara Piccini, Giuseppe Favacchio, Cristina Panico, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 28
Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta‐analysis
Paschalis Karakasis, Dimitrios Patoulias, Nikolaos Fragakis, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 1090-1104
Closed Access | Times Cited: 28
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
Yuan Lin, Te-Hsiung Wang, Ming‐Lung Tsai, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 24
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Lærke S. Gasbjerg, Mette M. Rosenkilde, Juris J. Meier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3079-3092
Closed Access | Times Cited: 24
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
О. М. Драпкина, А. V. Kontsevaya, А. М. Калинина, et al.
CARDIOVASCULAR THERAPY AND PREVENTION (2024) Vol. 23, Iss. 3, pp. 3696-3696
Open Access | Times Cited: 15
Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease
Paola Caruso, Maria Ida Maiorino, Miriam Longo, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241545-e241545
Open Access | Times Cited: 13
2024 Clinical practice guidelines for Chronic heart failure
А. S. Galyavich, S. N. Tereshchenko, T. M. Uskach, et al.
Russian Journal of Cardiology (2024) Vol. 29, Iss. 11, pp. 6162-6162
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top